title: Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals.
abstract: OBJECTIVE
  Oxidation of low density lipoproteins (LDL) is thought to be an important step in the development of atherosclerosis. Trace metals are involved in oxidative processes. It was of interest to determine whether lipid-lowering therapy with fluvastatin, a potent HMGCoA reductase inhibitor, affected LDL oxidation and trace metal levels.
  
  
  METHODS
  Twenty hypercholesterolemic patients were treated with fluvastatin (40 mg twice daily) or placebo for 8 weeks in a double-blind, randomized study. LDL composition, antioxidants and oxidizability as well as plasma zinc, copper, selenium and manganese concentrations were investigated.
  
  
  RESULTS
  After fluvastatin treatment, total cholesterol was reduced by 24%, triglycerides fell by 26% and plasma Zn fell by 8%. Cu, Se and Mn changed insignificantly. LDL were separated by ultracentrifugation. LDL were reduced by 18%, LDL-C by 29% and LDL-TG by 19%. The concentrations of alpha-tocopherol and retinol in LDL changed insignificantly. LDL preparations were incubated with copper ions (204 mumol.1(-1) LDL-C/3.2 mumol.1(-1) Cu) and formation of conjugated dienes was monitored at 234 nm for 5 h. Treatment with fluvastatin caused a reduction of diene production by 16% and of diene production rate by 14%, effects being significantly different from placebo (P = 0.02). The change of the lagtime did not reach significance; however, it was positively correlated with the change in LDL alpha-tocopherol. In the placebo group, no significant effects were observed.
  
  
  CONCLUSIONS
  Fluvastatin therapy had lipid-lowering and antioxidative effects.
authors.affiliation: Institut und Poliklinik für Klinische Stoffwechselforschung, Medizinische Fakultät, Technischen Universität Dresden, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Leonhardt
authors.forename: T
authors.initials: T
authors.lastname: Kurktschiev
authors.forename: D
authors.initials: D
authors.lastname: Meissner
authors.forename: P
authors.initials: P
authors.lastname: Lattke
authors.forename: C
authors.initials: C
authors.lastname: Abletshauser
authors.forename: G
authors.initials: G
authors.lastname: Weidinger
authors.forename: W
authors.initials: W
authors.lastname: Jaross
authors.forename: M
authors.initials: M
authors.lastname: Hanefeld
mesh_terms: D000924:Anticholesteremic Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000378:metabolism; D004311:Double-Blind Method; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D005260:Female; D000077340:Fluvastatin; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000378:metabolism*; D007211:Indoles / Q000494:pharmacology*; D050356:Lipid Metabolism; D008055:Lipids / Q000032:analysis*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008297:Male; D008670:Metals / Q000097:blood*; D008875:Middle Aged; D014801:Vitamin A / Q000378:metabolism; D014810:Vitamin E / Q000378:metabolism*
chemical_list: D000924:Anticholesteremic Agents; D000975:Antioxidants; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D008055:Lipids; D008077:Lipoproteins, LDL; D008670:Metals; D014801:Vitamin A; D014810:Vitamin E; D000077340:Fluvastatin